August 08, 2018 - Ra Pharmaceuticals, Inc. (NASDAQ:RARX) has filed a financial statement reporting Earnings Per Share Basic And Diluted of $-0 USD. Previously, on May 09, 2018, Ra Pharmaceuticals, Inc. reported Earnings Per Share Basic And Diluted of $-1 USD.

Period EndPeriodValue
2018-06-30 2018-Q2 -0.49
2018-03-31 2018-Q1 -0.61
2017-09-30 2017-Q3 -0.68
2017-06-30 2017-Q2 -0.56
2017-03-31 2017-Q1 -0.5
2016-12-31 2016-Q4 -0.73
2016-09-30 2016-Q3 -14.22
2016-06-30 2016-Q2 -8.9
2016-03-31 2016-Q1 -9.42
2015-12-31 2015-Q4 -8.63
2015-09-30 2015-Q3 -4.57
2015-06-30 2015-Q2 -5.14
2015-03-31 2015-Q1 -6.16
AllocatedShareBasedCompensationExpense CurrentFederalTaxExpenseBenefit CurrentForeignTaxExpenseBenefit CurrentStateAndLocalTaxExpenseBenefit DeferredFederalIncomeTaxExpenseBenefit DeferredForeignIncomeTaxExpenseBenefit DeferredStateAndLocalIncomeTaxExpenseBenefit DeferredTaxAssetsAccruedExpenses DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths FiniteLivedIntangibleAssetsAmortizationExpenseYearThree FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo GeneralAndAdministrativeExpense IncomeTaxExpenseBenefit IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate IncomeTaxReconciliationNondeductibleExpense IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets LeaseAndRentalExpense NonoperatingIncomeExpense OperatingExpenses OtherNoncashIncomeExpense OtherNonoperatingIncomeExpense PrepaidExpenseAndOtherAssetsCurrent ResearchAndDevelopmentExpense TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxAssetIncomeTaxExpense TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit

Related News Stories

Recent IPO Replimune: Oncolytic Viral Technology

2018-08-28 seekingalpha
Woburn, Massachusetts based Replimune launched its NASDAQ IPO recently, offering 7.4M shares at $15/share, raising $105M. (30-0)

Ra Pharmaceuticals: Is Trying To Copy What Works A Good Product Development Strategy?

2018-07-30 seekingalpha
Ra Pharma is developing RA101495, a C5 inhibitor and a potential competitor to Alexion's blockbuster Soliris. (7-0)

Insiders Are Bullish On Tiny Tonix (Again)

2018-07-24 seekingalpha
TNXP remains appropriate only for investors who can stomach the high risk in this potentially high-reward punt. (7-5)

Riding Ra Pharmaceuticals

2018-07-23 seekingalpha
Shares of Ra Pharmaceuticals (NASDAQ:RARX) have so far been a classically successful insider-inspired investment idea, with the volatility of this high-risk/high-reward development-stage biotech definitely biased to the upside so far in our 5-month holding period. (8-0)

6 Speculative BioHealth Analyst Stocks That Could Rally 50% to 300%

2018-07-21 247wallst
The bull market is now more than nine years old. Many investors have begun looking for new ideas and new strategies to generate income and gains, and the old strategy of buying every major market selling day has become less rewarding in 2018 versus the prior few years. It turns out that Wall Street brokerages and research shops still have many stock picks for big upside. (55-17)

CUSIP: 74933V108